Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Digitalis glycosides reduce cardiovascular death or worsening heart failure events in HFmrEF and HFrEF patients over a median of 36–37 months, supported by randomized trials and meta-analyses highlighting their role in select heart failure
Pharmacological activation of CXCR7 regulates platelet lipid metabolism, preserves mitochondrial function, and reduces procoagulant activity, offering a novel therapeutic strategy to mitigate thrombotic risk in cardiovascular diseases.
An analysis of elective endovascular repair outcomes in nonagenarians shows similar 30-day mortality to younger patients, supporting individualized treatment decisions based on risk rather than age alone.
This study reveals how cardiac resynchronization therapy (CRT) improves left ventricular function in heart failure patients and modulates systemic metabolomic profiles, highlighting differences between ischemic and nonischemic cardiomyopath
This study reveals genotype-specific differences in atrial fibrillation (AF) risk among dilated cardiomyopathy (DCM) patients, highlighting LMNA mutations as a major predictor of incident AF and its association with worse clinical outcomes,
Subclinical liver disease, marked by steatosis, fibrosis, and functional impairment, independently and synergistically increases cardiovascular disease risk. Incorporating non-invasive liver biomarkers could enhance CVD risk prediction and
Nighttime light exposure over 3 lux is linked to adverse cardiac remodeling, subclinical functional decline, and increased cardiovascular events, partly mediated by shorter sleep duration, underscoring the importance of dark nights and slee
Long-term cumulative exposure to wildfire smoke PM2.5 significantly increases cardiovascular hospitalizations among U.S. older adults, with notable risks in ischemic heart disease and arrhythmias, highlighting the need for targeted public h
This review synthesizes emerging evidence from the PROACT trials on genotype-first identification of subclinical coronary atherosclerosis using polygenic risk scores (PRS), highlighting feasibility, engagement, and high prevalence of silent
A large European cohort study identifies six circulating metabolites significantly associated with future stroke risk, highlighting their potential in improving early stroke risk prediction beyond classic risk factors.
This study reveals unique fatty acid and oxylipin metabolic signatures that differentiate isolated postcapillary pulmonary hypertension from combined pre- and postcapillary PH, highlighting potential biomarkers and therapeutic targets.
Clonal hematopoiesis of indeterminate potential (CHIP) poses a novel cardiovascular risk. This article explores challenges and strategies for designing cardiovascular outcomes trials tailored to CHIP’s genetic heterogeneity and clinical com
This multicentre study reveals that combining resting left atrial compliance with exercise stress echocardiography significantly improves diagnostic accuracy for HFpEF, potentially reducing the need for invasive testing in patients with une
The PORTHOS study reveals a 16.5% prevalence of heart failure among Portuguese adults aged 50+, with HFpEF constituting over 90% of cases, mostly undiagnosed, highlighting the need for enhanced screening strategies in aging populations.
A novel left atrial (LA) staging system, integrating hemodynamic load and contractile function, predicts new-onset atrial fibrillation risk in hypertrophic cardiomyopathy and may guide tailored AF surveillance.
Lactylation of HNRNPK at K405 links metabolic stress to inflammatory RNA splicing, promoting pathological Jag2 isoform expression and exacerbating myocardial ischemia/reperfusion injury, revealing novel therapeutic targets.
Rapid immunoassay-based classifiers accurately identify hyper- and hypoinflammatory subphenotypes in critically ill children, preserving prognostic and predictive utility and enabling precision therapies in acute pediatric cardiorespiratory
Initiation of menopausal hormone therapy during perimenopause or early postmenopause in women with vasomotor symptoms is associated with a reduced cardiovascular risk, especially among Black women and those starting therapy within 10 years
Comprehensive plasma proteomics reveal three molecular subtypes of transthyretin cardiac amyloidosis linked to distinct prognoses and differential tafamidis treatment responses, highlighting personalized therapeutic opportunities.
This study reveals that immune checkpoint and VEGF inhibitors, alone or combined, do not induce detectable arterial inflammation by PET, suggesting macrophage-driven plaque activation is not the main cause of related atherothrombotic events
Open language-specific specialty feeds and department pages.